Cardiff Net Income From Continuing Ops from 2010 to 2026
| CRDF Stock | USD 1.91 0.21 12.35% |
Net Loss | First Reported 2014-03-31 | Previous Quarter -13.9 M | Current Value -11.3 M | Quarterly Volatility 3.4 M |
Check Cardiff Oncology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cardiff Oncology's main balance sheet or income statement drivers, such as Selling General Administrative of 7.9 M, Other Operating Expenses of 59.6 M or Research Development of 44.5 M, as well as many indicators such as Price To Sales Ratio of 204, Dividend Yield of 0.0058 or PTB Ratio of 3.93. Cardiff financial statements analysis is a perfect complement when working with Cardiff Oncology Valuation or Volatility modules.
Cardiff | Net Income From Continuing Ops | Build AI portfolio with Cardiff Stock |
The Net Income From Continuing Ops trend for Cardiff Oncology offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Cardiff Oncology is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest Cardiff Oncology's Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of Cardiff Oncology over the last few years. It is Cardiff Oncology's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cardiff Oncology's overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
Cardiff Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | (26,006,712) | |
| Coefficient Of Variation | (49.24) | |
| Mean Deviation | 11,254,766 | |
| Median | (24,906,744) | |
| Standard Deviation | 12,805,077 | |
| Sample Variance | 164T | |
| Range | 33.6M | |
| R-Value | (0.82) | |
| Mean Square Error | 56.6T | |
| R-Squared | 0.68 | |
| Significance | 0.000051 | |
| Slope | (2,085,346) | |
| Total Sum of Squares | 2623.5T |
Cardiff Net Income From Continuing Ops History
About Cardiff Oncology Financial Statements
Cardiff Oncology stakeholders use historical fundamental indicators, such as Cardiff Oncology's Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Although Cardiff Oncology investors may analyze each financial statement separately, they are all interrelated. For example, changes in Cardiff Oncology's assets and liabilities are reflected in the revenues and expenses on Cardiff Oncology's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Cardiff Oncology. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Loss | -40.9 M | -42.9 M |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out the analysis of Cardiff Oncology Correlation against competitors. For more detail on how to invest in Cardiff Stock please use our How to Invest in Cardiff Oncology guide.You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Can Biotechnology industry sustain growth momentum? Does Cardiff have expansion opportunities? Factors like these will boost the valuation of Cardiff Oncology. Projected growth potential of Cardiff fundamentally drives upward valuation adjustments. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Cardiff Oncology demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Earnings Share (0.79) | Revenue Per Share | Quarterly Revenue Growth (0.27) | Return On Assets | Return On Equity |
Understanding Cardiff Oncology requires distinguishing between market price and book value, where the latter reflects Cardiff's accounting equity. The concept of intrinsic value - what Cardiff Oncology's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Market sentiment, economic cycles, and investor behavior can push Cardiff Oncology's price substantially above or below its fundamental value.
It's important to distinguish between Cardiff Oncology's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cardiff Oncology should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Cardiff Oncology's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.